Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1170868
PUBLISHER: Grand View Research | PRODUCT CODE: 1170868
U.S. Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain, Non-cold Chain), By Service, By Product Type (Specialty Drug), And Segment Forecasts, 2022 - 2030
PUBLISHED:
PAGES: 78 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Biopharmaceutical Third-party Logistics Market Growth & Trends:
The U.S. biopharmaceutical third-party logistics market size is expected to reach USD 87.2 billion by 2030, expanding at a CAGR of 7.3% over the forecast period, according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.
The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.
The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.
U.S. Biopharmaceutical Third-party Logistics Market Highlights:
- Non-cold chain logistics held the largest market share of 80.2% owing to the sales of a large number of drugs that do not require any temperature control
- The cold chain logistics segment is projected to witness the fastest CAGR of 10.1% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
- The increasing demand for the COVID-19 vaccine is a major contributor to the market growth. Furthermore, the rising trend of outsourcing logistics services is also fueling the growth
- Warehousing and storage held the largest market share of 43.4% share due to the growing demand for storage
- Specialty drugs dominated the market with the largest share of 39.2% in 2021 due to substantial growth in specialty pharma
Product Code: GVR-4-68038-381-2
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation & Scope
- 1.1.1 Supply Chain
- 1.1.2 Services Type
- 1.1.3 Product Type
- 1.1.4 Regional Scope
- 1.1.5 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR'S Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis (Model 1)
- 1.6.2 Volume Price Analysis (Model 2)
- 1.7 List of Secondary Sources
- 1.8 List of Primary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
- 1.10.1 Objective - 1
- 1.10.2 Objective - 2
- 1.10.3 Objective - 3
- 1.10.4 Objective - 4
Chapter 2 Executive Summary
- 2.1 Market Outlook
Chapter 3 Market Definition
- 3.1.1 By Supply Chain
- 3.1.2 By Services Type
- 3.1.3 By Product type
Chapter 4 U.S. Biopharmaceutical Third-party Logistics Market: Variables, Trends, & Scope
- 4.1 Market Segmentation and Scope
- 4.2 Market Driver Analysis
- 4.2.1 Technological advancements in logistics
- 4.2.2 Growing applications of reverse logistics in the biopharmaceutical industry
- 4.2.3 Rising demand for cold chain logistics
- 4.3 Market Restraint Analysis
- 4.3.1 Compliance Issues While Outsourcing
- 4.4 Penetration & Growth Prospect Mapping
- 4.5 Porter's Five Forces Analysis
- 4.6 PESTEL Analysis
- 4.7 Covid Impact and Reformation Analysis
Chapter 5 Qualitative Information for Hub Services, Copay, and Adherence
- 5.1 Hub Services
- 5.2 Copay
- 5.3 Adherence
Chapter 6 U.S. Biopharmaceutical Third-party Logistics Market: Supply Chain Segment Analysis
- 6.1 U.S. Biopharmaceutical Third-party Logistics Market: Market Share Analysis, 2021 & 2030
- 6.2 Cold Chain Logistics
- 6.2.1 Cold Chain Logistics market, 2018 - 2030 (USD Billion)
- 6.3 Non-cold Chain Logistics
- 6.3.1 Non-cold Chain Logistics market, 2018 - 2030 (USD Billion)
Chapter 7 U.S. Biopharmaceutical Third-party Logistics Market: Services Type Segment Analysis
- 7.1 U.S. Biopharmaceutical Third-party Logistics Market: Market Share Analysis, 2021 & 2030
- 7.2 Transportation
- 7.2.1 Transportation market, 2018 - 2030 (USD Billion)
- 7.2.2 Air freight
- 7.2.2.1 Air freight market, 2018 - 2030 (USD Billion)
- 7.2.3 Sea freight
- 7.2.3.1 Sea freight market, 2018 - 2030 (USD Billion)
- 7.2.4 Overland transportation
- 7.2.4.1 Overland transportation market, 2018 - 2030 (USD Billion)
- 7.3 Warehousing and Storage
- 7.3.1 Warehousing and Storage market, 2018 - 2030 (USD Billion)
- 7.4 Other Services
- 7.4.1 Other Services market, 2018 - 2030 (USD Billion)
Chapter 8 U.S. Biopharmaceutical Third-party Logistics Market: Product Type Segment Analysis
- 8.1 U.S. Biopharmaceutical Third-party Logistics Market: Market Share Analysis, 2021 & 2030
- 8.2 Specialty Drugs
- 8.2.1 Specialty Drugs market, 2018 - 2030 (USD Billion)
- 8.3 Generics
- 8.3.1 Generics market, 2018 - 2030 (USD Billion)
- 8.4 Plasma-Derived Products
- 8.4.1 Plasma Derived Products market, 2018 - 2030 (USD Billion)
- 8.5 Others
- 8.5.1 Others market, 2018 - 2030 (USD Billion)
Chapter 9 Company Profiles
- 9.1 Company Profiles
- 9.1.1 FedEx
- 9.1.1.1 Company overview
- 9.1.1.2 Financial performance
- 9.1.1.3 Product benchmarking
- 9.1.2 DHL International GmbH
- 9.1.2.1 Company overview
- 9.1.2.2 Financial performance
- 9.1.2.3 Product benchmarking
- 9.1.3 SF Express
- 9.1.3.1 Company overview
- 9.1.3.2 Financial performance
- 9.1.3.3 Product benchmarking
- 9.1.4 United Parcel Service of America, Inc.
- 9.1.4.1 Company overview
- 9.1.4.2 Financial performance
- 9.1.4.3 Product benchmarking
- 9.1.4.4 Strategic initiatives
- 9.1.5 AmerisourceBergen Corporation
- 9.1.5.1 Company overview
- 9.1.5.2 Financial performance
- 9.1.5.3 Product benchmarking
- 9.1.6 DB Schenker
- 9.1.6.1 Company overview
- 9.1.6.2 Financial performance
- 9.1.6.3 Product benchmarking
- 9.1.7 KUEHNE + NAGEL
- 9.1.7.1 Company overview
- 9.1.7.2 Financial performance
- 9.1.7.3 Product benchmarking
- 9.1.8 Kerry Logistics Network Limited
- 9.1.8.1 Company overview
- 9.1.8.2 Financial performance
- 9.1.8.3 Product benchmarking
- 9.1.9 Agility
- 9.1.9.1 Company overview
- 9.1.9.2 Financial performance
- 9.1.9.3 Product benchmarking
- 9.1.1 FedEx
Product Code: GVR-4-68038-381-2
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 U.S. Biopharmaceutical Third-party Logistics Market, By Supply Chain, 2018 -2030 (USD Billion)
- Table 4 U.S. Biopharmaceutical Third-party Logistics Market, By Service Type, 2018 -2030 (USD Billion)
- Table 5 U.S. Biopharmaceutical Third-party Logistics Market, By Transportation, 2018 -2030 (USD Billion)
- Table 6 U.S. Biopharmaceutical Third-party Logistics Market, By Product Type, 2018 -2030 (USD Billion)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Commodity Flow Analysis
- Fig. 9 Volume Price Analysis
- Fig. 10 U.S. Biopharmaceutical Third-party Logistics market snapshot (2020)
- Fig. 11 U.S. Biopharmaceutical Third-party Logistics market segmentation
- Fig. 12 Market driver relevance analysis (Current & future impact)
- Fig. 13 Market restraint relevance analysis (Current & future impact)
- Fig. 14 Penetration & growth prospect mapping
- Fig. 15 Porter's five forces analysis
- Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 17 Reasons for non-adherence in the U.S.
- Fig. 18 U.S. Biopharmaceutical Third-party Logistics market supply chain outlook: Segment dashboard
- Fig. 19 U.S. Biopharmaceutical Third-party Logistics market: Supply chain movement analysis
- Fig. 20 Cold chain logistics market, 2018 - 2030 (USD Billion)
- Fig. 21 Non-cold chain logistics market, 2018 - 2030 (USD Billion)
- Fig. 22 U.S. Biopharmaceutical Third-party Logistics market services type outlook: Segment dashboard
- Fig. 23 U.S. Biopharmaceutical Third-party Logistics market: Services Type movement analysis
- Fig. 24 Transportation market, 2018 - 2030 (USD Billion)
- Fig. 25 Air freight market, 2018 - 2030 (USD Billion)
- Fig. 26 Sea freight market, 2018 - 2030 (USD Billion)
- Fig. 27 Overland transportation market, 2018 - 2030 (USD Billion)
- Fig. 28 Warehousing and storage market, 2018 - 2030 (USD Billion)
- Fig. 29 Other services market, 2018 - 2030 (USD Billion)
- Fig. 30 U.S. Biopharmaceutical Third-party Logistics market product type outlook: Segment dashboard
- Fig. 31 U.S. Biopharmaceutical Third-party Logistics market: Product type movement analysis
- Fig. 32 Specialty drugs market, 2018 - 2030 (USD Billion)
- Fig. 33 Generics market, 2018 - 2030 (USD Billion)
- Fig. 34 Plasma-derived products market, 2018 - 2030 (USD Billion)
- Fig. 35 Others market, 2018 - 2030 (USD Billion)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.